**Charity number: 1003619 Company number: 2626039** 

## **THE BLOOD CARE FOUNDATION** 

**TRUSTEES’ REPORT AND UNAUDITED FINANCIAL STATEMENTS** 

**FOR THE YEAR ENDED 31 DECEMBER 2022** 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **CONTENTS** 

|Legal and Administrative information|1|
|---|---|
|Report of the Trustees|2 - 7|
|Independent Examiner’s Report|8|
|Statement of Financial Activities|9|
|Balance Sheet|10|
|Notes to the Financial Statements|11 - 16|



**Detailed income and expenditure account and summaries** 



**THE BLOOD CARE FOUNDATION (A company limited by guarantee)** 

## **LEGAL AND ADMINISTRATIVE INFORMATION** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

|**Trustees**|Mr J. Bruce, Chairman|
|---|---|
||Mr M.G. Bruce, Chairman Emeritas|
||Dr J. Barrett|
||Dr R.M. Dawood|
||Dr C.P. Lee O.St.J|
||Mr B.J. Pearson|
||Col. M.J.G. Thomas|
|**Company registered number**|2626039|
|**Charity registered number**|1003619|
|**Registered office**|North House|
||198 High Street|
||Tonbridge|
||Kent|
||TN9 1BE|
|**Company secretary**|M.F. Gunton|
|**Chief executive officer**|J.N. Bruce|
|**Independent examiner**|A.S. Healey FCA CTA DChA|
||Lindeyer Francis Ferguson Limited|
||Chartered Accountants|
||North House|
||198 High Street|
||Tonbridge|
||Kent|
||TN9 1BE|
|**Bankers**|The Royal Bank of Scotland|
||London Drummonds Branch|
||49 Charing Cross|
||London|
||SW1A 2DX|



Page 1 



**THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **TRUSTEES’ REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

The Trustees (who are also directors of the charity for the purposes of the Companies Act) present their annual report together with the financial statements of The Blood Care Foundation (the company) for the year ended 31 December 2022. 

The Trustees confirm that the report and financial statements of the charity comply with the current statutory requirements, the requirements of the company's governing document, and the provisions of "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019) (Charities SORP (FRS 102)). The Legal and Administrative information on page 1 forms part of this report. 

## **Structure, governance and management** 

## **a. Constitution** 

The company is registered as a charitable company limited by guarantee incorporated on 2 July 1991 and governed by a Memorandum and Articles of Association, as revised on 24 April 2013. 

The principal object of the company continued to be the supply and distribution of screened blood, resuscitation fluids and sterile transfusion equipment. 

In setting objectives and planning for activities, the Trustees have given due consideration to general guidance published by the Charity Commission relating to public benefit. 

## **b. Method of appointment or election of Trustees** 

Potential new trustees are usually identified by the directors as being suitable candidates to approach. If that person is prepared to consider such an appointment and they have the required ability and commitment, they are invited to join the Foundation. The new trustee is invited to sign a letter of application, following which they are elected to the board. 

Appointments made during the year are ratified at the following AGM. Given the size of the charity, there are no formal policies in place for the induction and training of Trustees. However, each trustee, from their own knowledge and experience, is aware of their responsibilities and is required to keep up to date through technical reading and personal development. 

## **c. Organisational structure and decision making** 

The Foundation is run by its directors who are also the Trustees of the charity and members of the company. The Trustees bring a broad range of knowledge to the Foundation and, under the chairmanship of Julian Bruce, are responsible for managing the current activities of the Foundation and developing its future plans. 

Page 2 



**THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **TRUSTEES’ REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **Members' liability** 

The members of the company guarantee to contribute an amount not exceeding £1 to the assets of the charity in the event of winding up. 

## **Review of activities for the public benefit and future developments** 

The Trustees recognise and confirm their awareness of the need for the activities of the Foundation to be for the public benefit. 

When the Foundation was first established, its aims and objectives were based on the principle that each country should, in an emergency, be responsible for the provision of blood at an acceptable quality, for its own nationals. 

From its inception, the Foundation has been making and continues to make part of its practical contributions to this principle through the training of blood banking staff and by providing a consultancy service in Transfusion Medicine to treating doctors. 

Each time the BCF Quality Assurance Manager audits one of its own, or another organisation's dedicated blood banks in a developing country, time is taken to train the local blood bankers in the latest techniques of blood banking, to help increase their own knowledge and contribute to the overall development of blood banking standards in that particular country. 

As in-depth Transfusion Medicine does not normally form part of the standard medical training in many countries, the Foundation provides a world-wide consultancy support service to treating doctors when they are faced with difficult transfusion decisions. 

## **Chairman’s Report** 

The need for Screened Blood, Rabies Immunoglobulin, their Availability and Quality. 

The difficulties of finding adequate supplies of screened blood in 2022 continued, partly due to the ongoing concerns about Covid, causing a continuing shortage of blood donors during the year. 

In contrast, the need to provide blood throughout the developing world to treat Malaria, HIV and the many other diseases requiring a blood transfusion, quite apart from the ever present risks from accidents and rabies infections, remained unchanged. 

## Blood 

One of the greatest benefits of Blood Care Programme membership is the possibility of receiving blood in an emergency from one of the world’s internationally recognised Blood Transfusion Centres. Their active support for the Foundation, despite their own shortages of supplies, was greatly appreciated by the Trustees and has allowed this vital service to continue unhindered to its members. 

Page 3 



**THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **TRUSTEES’ REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## Rabies 

Whilst there is little awareness of the risk from rabies in the Western world, this disease is still rampant in many parts of Africa and the Far East, exposing expatriates and travellers alike to this life-threatening illness. Unless treated with rabies immunoglobulin, which is not only very expensive but extremely difficult to obtain, a person is almost certain to die. For this reason, the Foundation holds its own stock of human rabies immunoglobulin for immediate despatch to the patient. 

## Consultancy Services 

Medical staff in the developing world frequently lack the infrastructure to enable them to discuss a complicated issue with senior doctors, which is particularly important in a medical emergency.  The Foundation’s consultancy service provides doctors in the field with access to the latest transfusion information should they be facing a particular problem. 

## Website 

The Trustees decided to modernise and redesign the Foundation’s website to help make it more attractive and responsive to the needs of potential members of the Blood Care Programme, enabling them to easily access all the relevant information they might need. 

The updated site will be available at www.bloodcarefoundation.org.uk by the end of April 2023. 

## Quality 

The importance of the quality of the screened blood made available to members cannot be overestimated. 

To illustrate its value, the secretary of a senior diplomat in a developing country was travelling to work when her car was involved in a serious road accident; she was taken to the leading hospital in the city where she received a blood transfusion as part of her treatment. 

Unfortunately, the blood she received had been inadequately screened, leading her to become infected with HIV and Malaria on top of all her other injuries. 

The quality of the blood made available to its members lies at the heart of the Foundation’s services; to achieve the highest possible standards, the charity’s work is guided and supervised by its External Audit Panel, the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), its Advisory Council and the Charity Commission. 

## Finance 

One of the results of Covid-19 has been the major decline in tourism on a global scale, leading to a reduction in those requiring protection when travelling to developing parts of the world such as Africa and Asia. 

Page 4 



**THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **TRUSTEES’ REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

However, this protection was still required by the many companies with expatriate staff in these regions which helped the Foundation to generate a gross income of £191,830 and balance its accounts to close the year with a small net expenditure of £846. 

At year-end the ring-fenced Fund for Projects and the General Fund stood at £145,048 and £16,788 respectively, resulting in total funds of the Foundation of £161,836. 

The charity aims to slowly build up the level of reserves for operational purposes whilst maintaining designated funds which are built up from special receipts (such as legacies) and which will be used to fund special projects. 

## Membership 

The absence of many travellers during the year resulted in few new individual members joining the Blood Care Programme.  However, the membership of the many companies, recognising its life-saving potential, remained unchanged, especially in view of the difficulties in accessing screened blood or treatment for rabies in an emergency. 

## Ukraine 

In April 2022, a private initiative was launched to collect a range of basic supplies to help support the residents in Kiev. 

A large van was donated to serve as an ambulance and a jeep was donated to provide transportation for medical staff; these were then filled with medical supplies, clothing, bedding, food, toys and other practical supplies. 

After a 22-hour drive to the border between Poland and Ukraine, the aid was taken into the centre of Lviv for onward transportation into the heart of the war. In March 2023, the vehicles continue to be used around the clock to evacuate injured civilians out of Odessa and into safer converted hospital bunkers. The food delivered provided over 5,000 much needed meals to the frontline medical teams and to local civilians without homes, through makeshift soup kitchens. Children were able to benefit from clothes to keep them warm and a toy to alleviate some of the misery of the daily horrors. 

The Foundation donated some £1,500 worth of medical equipment to this shipment. 

## Management 

None of the Foundation’s services would have been and continue to be possible without the dedicated support of its Board of very experienced Trustees, each of whom is a specialist in their chosen field of medicine and business. Their unwavering encouragement is ably strengthened by the Foundation’s Advisory Council and the External Audit Panel. The Foundation owes each of their members its sincere gratitude for their unstinting, honorary service. 

Page 5 



**THE BLOOD CARE FOUNDATION (A company limited by guarantee)** 

## **TRUSTEES’ REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## Conclusion 

Despite all the challenges experienced in the past year, the Trustees are looking forward to a great deal of increased travel activity in 2023 and to being able to make its life-saving services available to very many more people throughout the world. 

## **Relationship with other organisations** 

The Foundation has a relationship with Asclepius (International) Limited. This company, which is beneficially owned by members of the Bruce family, is a UK based organisation active in the fields of expatriate health and general medical services. Asclepius provides the Foundation with the clinical and general management services, quality assurance, legal and administrative services which are vital to the operations of the charity. Although the Foundation can provide these services itself, they have been outsourced to protect the Foundation, by enabling it to operate with the minimum level of overheads. Asclepius has been instrumental in its formation and has contributed to its development by charging less than the full fees payable by the Foundation (see note 11). 

Asclepius arranges the recruitment of administrative staff for the Foundation and pays their fees or salaries. The objective of this arrangement is to protect the Foundation, so that if its income fell for any reason, the Foundation would not be left with an unsustainable overhead to carry. 

## **Trustees' responsibilities statement** 

The Trustees (who are also directors of The Blood Care Foundation for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102). 

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to: 

- select suitable accounting policies and then apply them consistently; 

- observe the methods and principles in the Charities SORP FRS 102; 

- make judgments and accounting estimates that are reasonable and prudent; 

- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation. 

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the 

Page 6 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

**TRUSTEES’ REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. 

This report has been prepared in accordance with the provisions applicable to small companies subject to the small companies’ regime in Part 15 of the Companies Act 2006 

This report was approved by the Trustees on 18 August 2023 and signed on their behalf by: 

## **Michael G. Bruce, Chairman Emeritus & Trustee** 

Page 7 



## **THE BLOOD CARE FOUNDATION (A company limited by guarantee)** 

## **INDEPENDENT EXAMINER’S REPORT** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

I report to the charity trustees on my examination of the accounts of the company for the year ended 31 December 2022. 

## **Responsibilities and basis of report** 

As the trustees of the company (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 (‘the 2006 Act’). 

Having satisfied myself that the accounts of the company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the company’s accounts carried out under section 145 of the Charities Act 2011 (‘the 2011 Act’). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act. 

## **Independent examiner's statement** 

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe: 

- accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or 

- the accounts do not accord with those records; or 

- the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a ‘true and fair view’ which is not a matter considered as part of an independent examination; or 

- the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)]. 

In my opinion, in order to enable a proper understanding of the accounts to be reached, attention should be drawn to the disclosures made in Note 2.1 to the financial statements concerning the accounting treatment of a liability disclosed as a contingent liability. 

**Amy Healey FCA CTA DChA                                                                                      Dated:** 6 September 2023 **Lindeyer Francis Ferguson Limited** Chartered Accountants North House 198 High Street Tonbridge Kent TN9 1BE 

Page 8 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **STATEMENT OF FINANCIAL ACTIVITIES (incorporating income and expenditure account)** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

|**Notes**<br>**Income from:**<br>Donations and legacies<br>Charitable activities<br>**3**<br>Investments<br>Total income<br>**Expenditure on:**<br>Charitable activities<br>**4**<br>Total expenditure<br>**Net (expenditure)/income and net movement in funds**<br>**Reconciliation of funds:**<br>Total funds brought forward<br>Total funds carried forward<br>**10**|_Unrestricted_<br>_funds_<br>_2022_<br>_£_<br>-<br>191,830<br>41<br>191,871<br>192,717<br>192,717<br>**( 846)**<br>162,682<br>**161,836**|_Unrestricted_<br>_funds_<br>_2021_<br>_£_<br>34<br>223,826<br>11|
|---|---|---|
|||223,871|
|||223,471|
|||223,471|
|||**400**<br>162,282|
|||**162,682**|



Page 9 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **BALANCE SHEET** _**AS AT 31 DECEMBER 2022**_ 

|**Notes**<br>**Current assets**<br>Debtors<br>**8**<br>Cash at bank and in hand<br>**Creditors: amounts falling due**<br>**within one year**<br>**9**<br>**Net current assets**<br>**Net assets**<br>**The funds of the charity**<br>Unrestricted funds<br>**10**|_£_<br>56,230<br>210,102<br>266,332<br>( 104,496)|_2022_<br>_£_<br>161,836<br>**161,836**<br>**161,836**|_£_<br>80,869<br>139,023<br>219,892<br>( 57,210)|_2021_<br>_£_<br>162,682|
|---|---|---|---|---|
|||||**162,682**|
|||||**162,682**|



For the financial year ended 31 December 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. 

Directors' responsibilities: 

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476; 

- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements. 

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime. 

The financial statements were approved by the Trustees on 18 August 2023 and signed on their behalf by: 

## **Michael G. Bruce, Chairman Emeritus & Trustee** 

## **Company Registration Number: 2626039** 

Page 10 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **1 Status** 

The Blood Care Foundation is a private charitable company limited by guarantee incorporated in England & Wales. Its registered address is North House, 198 High Street, Tonbridge, Kent, TN9 1BE. 

## **2 Accounting policies** 

The principal accounting policies adopted, judgements and key sources of estimation uncertainty in the preparation of the financial statements are as follows: 

## **2.1 Basis of preparation** 

The financial statements have been prepared in accordance with "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006. 

The trustees have concluded that the financial statements give a true and fair view of the charity’s financial position and financial performance. The charity has complied with FRS 102 except that it has departed from Section 21 ‘Provisions and Contingencies’ to the extent necessary to give a true and fair view. The charity has accounted for a contingent liability of £211,499 at the balance sheet date, as shown in note 11. Section 21 of FRS 102 requires recognition of a provision in the balance sheet where it is probable that the obligation will be repaid but the timing or amount is uncertain. In recent years there has been a partial repayment of the amount due which makes it probable that some or all of the debt will be repaid. However the trustees consider that to include a provision in the accounts would not present a true and fair view. The charity is only required to repay the balance out of future income taking into account the charity’s resources. In the event of the charity winding up the amount due would be waived. The Trustees therefore consider that disclosure of a contingent liability gives a true and fair view. 

The accounts are presented in pounds sterling and rounded to the nearest pound. 

The Blood Care Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes. 

There are no material uncertainties about the charity's ability to continue, and so the going concern basis of accounting has been adopted. 

Page 11 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **2 Accounting policies (continued)** 

## **2.2 Income** 

Total income comprises the invoiced value of membership fees, other services supplied to third parties and interest received. Income from membership fees is recognised over the period covered by the membership subscription on a straight-line basis. Income from other services is recognised in the period when the service is performed.  Interest is recognised in the period to which it relates. 

Income from legacies is recognised at the earlier of receipt of the legacy or the date of approval for distribution. 

## **2.3 Expenditure and liabilities** 

Liabilities, and related expenditure, are recognised when a present legal or constructive obligation exists at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefits will be required to settle the obligation, and the amount can be measured or estimated reliably. 

Charitable activities includes expenditure on the supply and distribution of blood and equipment. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them including governance costs incurred in connection with administration of the company and compliance with constitutional and statutory requirements. 

## **2.4 Financial instruments** 

The charity only has financial instruments of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value. 

## **2.5 Foreign currencies** 

Monetary assets and Iiabilities denominated in foreign currencies are translated into sterling at rates of exchange ruling at the balance sheet date. 

Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. 

Exchange gains and losses are recognised in the Statement of Financial Activities. 

Page 12 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **3 Income from charitable activities** 

|Membership fees<br>Special project fees<br>**4**<br>**Expenditure on charitable activities**<br>**Direct costs**<br>Blood supplies and testing<br>Transport and shipping<br>Clinical and quality assurance<br>Service fees<br>**Support costs**<br>Administration and support fees<br>Alarm centre<br>Telephone and fax<br>Printing and stationery<br>Postage<br>Travel and subsistence<br>Rent and rates<br>Exchange differences<br>Other office costs<br>Legal and professional fees<br>Marketing and promotion<br>**Governance costs**<br>Independent Examiners' remuneration<br>Independent Examiners' other services|_2022_<br>_£_<br>58,261<br>133,569<br>191,830<br>_2022_<br>_£_<br>70,102<br>41,986<br>49,998<br>28,304<br>5,826<br>( 4,963)<br>873<br>-<br>491<br>486<br>4,224<br>( 16,692)<br>5,649<br>1,677<br>1,000<br>2,456<br>1,300<br>192,717|_2021_<br>_£_<br>71,725<br>152,101|
|---|---|---|
|||223,826|
|||_2021_<br>_£_<br>102,586<br>14,931<br>44,800<br>36,690<br>7,173<br>2,448<br>1,522<br>375<br>533<br>-<br>4,224<br>( 1,484)<br>5,620<br>487<br>-<br>2,266<br>1,300|
|||223,471|



**5 Turnover** 79.94% of the charity's income (2021 - 75.38%) is attributable to geographical markets outside the United Kingdom. 

Page 13 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **6 Net (expenditure) / income** 

|**Net (expenditure) / income**|||
|---|---|---|
|This is stated after charging:<br>Independent Examiners' remuneration<br>Independent Examiners' other services|_2022_<br>_£_<br>2,456<br>1,300<br>3,756|_2021_<br>_£_<br>2,266<br>1,300|
|||3,566|



**7 Trustees' remuneration and expenses** Key management personnel are defined as the Trustees only. During the year, no Trustees received any remuneration or benefits in kind for their services as trustees (2021: £nil). 

In 2022 no trustees were reimbursed for expenses (2021: £nil). 

## **8 Debtors** 

|Fees receivable<br>Deferred expenditure|_2022_<br>_£_<br>51,827<br>4,403<br>56,230|_2021_<br>_£_<br>76,035<br>4,834|
|---|---|---|
|||80,869|



Page 14 



## **THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **9 Creditors: amounts falling due within one year** 

|Trade creditors<br>Accruals and deferred income<br>**Fees invoiced in advance included in deferred income**<br>Balance at 1 January 2022<br>New amounts invoiced<br>Amounts released to income for services rendered<br>Balance at 31 December 2022|_2022_<br>_£_<br>83,600<br>20,896<br>104,496<br>_£_<br>9,668<br>14,906<br>( 9,668)<br>14,906|_2021_<br>_£_<br>37,375<br>19,835|
|---|---|---|
|||57,210|
|||_£_<br>9,978<br>9,668<br>( 9,978)|
|||9,668|



## **10 Movement in funds** 

|**_Current year_**<br>**Unrestricted funds**<br>General fund<br>Designated funds:<br>Fund For Projects|**Brought**<br>**forward**<br>16,094<br>146,588<br>162,682|**Income**<br>191,871<br>191,871|( 191,177)<br>( 1,540)<br>( 192,717)<br>**Expenditure**|**Carried**<br>**forward**<br>16,788<br>145,048|
|---|---|---|---|---|
|||||161,836|



The designated fund was created to fund special projects following the receipt of legacy income in prior years. The trustees have decided that the funds should be designated for a marketing programme and for other special, designated projects, bearing the name of the donor where appropriate. 

|**_Prior year_**<br>**Unrestricted funds**<br>General fund<br>Designated funds:<br>Fund For Projects|**Brought**<br>**forward**<br>15,694<br>146,588<br>162,282|**Income**<br>223,871<br>-<br>223,871|**Expenditure**<br>( 223,471)<br>-<br>( 223,471)|**Carried**<br>**forward**<br>16,094<br>146,588|
|---|---|---|---|---|
|||||162,682|



## _**Prior year**_ 

Page 15 



**THE BLOOD CARE FOUNDATION** 

## **(A company limited by guarantee)** 

## **NOTES TO THE FINANCIAL STATEMENTS** _**FOR THE YEAR ENDED 31 DECEMBER 2022**_ 

## **11 Contingent assets and liabilities** 

## _Contingent liability_ 

A contingent liability exists towards Asclepius (International) Limited, which has charged less than the full fees payable by The Blood Care Foundation for services provided. This contingent liability amounts to £211,449 at 31 December 2022 (2021: £216,449) and is only payable in the future out of surplus income (if any) at such time and in such manner as the Trustees shall consider appropriate. 

## **12 Related party transactions** 

Asclepius (International) Limited is a supporter of the objectives of the Blood Care Foundation having been responsible for its formation. It is beneficially owned by members of the Chairman's family and provides service, adminstration and support fees to the Foundation. 

|provides service, adminstration and support fees to the Foundation.|||
|---|---|---|
||_2022_|_2021_|
||_£_|_£_|
|Service fees, management and administrative services|34,130|43,863|
|Office rent|4,224|4,224|



At the balance sheet date £39,909 (2021: £24,589) was due to Asclepius (International) Limited and this is included in creditors. 

Clinical and quality assurance fees includes £46,460 (£43,845) paid to MG & SJ Enterprises of which trustee Col. M.J.G Thomas is a partner. 

Page 16 

